AKBA Akebia Therapeutics

NASDAQ
$0.92

Akebia Therapeutics (AKBA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with AKBA's own trailing one-year pace, with 94% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
1
1 transaction
Insiders selling
6
16 transactions
Purchases
$86.6K
69,270 shares
Sales
$963.0K
704,058 shares
Net activity
-$876.4K
purchases less sales

How much of that selling was preplanned? 94% planned / 6% discretionary

10b5-1 plan sales $900.8K 15 transactions · 648,039 shares
Discretionary sales $62.2K 1 transaction · 56,019 shares

Largest single sale: $159.7K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: March 4, 2026 , by Butler John P. .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Ostrowski Erik SVP, CFO, CBO & Treasurer Sell 56,019 $1.11 $62.2K 616,616 −8.3% of holding
Butler John P. CEO and President Buy 69,270 $1.25 $86.6K 3,367,064
Butler John P. 4 fills CEO and President Sell 10b5-1 341,305 $1.39 $474.4K 3,417,189 −9.1% of holding
Grund Nicholas 2 fills Chief Commercial Officer Sell 10b5-1 84,829 $1.39 $117.9K 592,994 −12.5% of holding
Rucci Carolyn M. 3 fills SVP, Chief Legal Officer Sell 10b5-1 69,772 $1.39 $97.0K 641,304 −9.8% of holding
Burke Steven Keith 3 fills SVP, Chief Medical Officer Sell 10b5-1 67,658 $1.39 $94.0K 994,508 −6.4% of holding
Malabre Richard C 2 fills SVP, Chief Accounting Officer Sell 10b5-1 49,524 $1.39 $68.8K 312,772 −13.7% of holding
Ostrowski Erik SVP, CFO, CBO & Treasurer Sell 10b5-1 34,951 $1.39 $48.6K 672,635 −4.9% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.